ALIMERA SCIENCES INC (ALIM) Stock Fundamental Analysis

NASDAQ:ALIM • US0162592028

5.54 USD
-0.01 (-0.18%)
At close: Sep 13, 2024
5.54 USD
0 (0%)
After Hours: 9/13/2024, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, ALIM scores 4 out of 10 in our fundamental rating. ALIM was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ALIM have multiple concerns. ALIM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year ALIM has reported negative net income.
  • In the past year ALIM has reported a negative cash flow from operations.
  • ALIM had negative earnings in each of the past 5 years.
  • ALIM had a negative operating cash flow in each of the past 5 years.
ALIM Yearly Net Income VS EBIT VS OCF VS FCFALIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of ALIM (-10.16%) is better than 72.82% of its industry peers.
  • With a decent Return On Equity value of -39.38%, ALIM is doing good in the industry, outperforming 62.05% of the companies in the same industry.
  • ALIM has a Return On Invested Capital of 0.12%. This is in the better half of the industry: ALIM outperforms 76.92% of its industry peers.
Industry RankSector Rank
ROA -10.16%
ROE -39.38%
ROIC 0.12%
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALIM Yearly ROA, ROE, ROICALIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800

1.3 Margins

  • ALIM has a better Operating Margin (0.20%) than 76.92% of its industry peers.
  • ALIM has a better Gross Margin (86.39%) than 90.26% of its industry peers.
  • In the last couple of years the Gross Margin of ALIM has remained more or less at the same level.
Industry RankSector Rank
OM 0.2%
PM (TTM) N/A
GM 86.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
ALIM Yearly Profit, Operating, Gross MarginsALIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ALIM has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ALIM has more shares outstanding
  • ALIM has a better debt/assets ratio than last year.
ALIM Yearly Shares OutstandingALIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ALIM Yearly Total Debt VS Total AssetsALIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • ALIM has an Altman-Z score of -1.37. This is a bad value and indicates that ALIM is not financially healthy and even has some risk of bankruptcy.
  • ALIM has a Altman-Z score (-1.37) which is comparable to the rest of the industry.
  • ALIM has a Debt/Equity ratio of 1.80. This is a high value indicating a heavy dependency on external financing.
  • ALIM's Debt to Equity ratio of 1.80 is on the low side compared to the rest of the industry. ALIM is outperformed by 78.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Altman-Z -1.37
ROIC/WACC0.01
WACC9.95%
ALIM Yearly LT Debt VS Equity VS FCFALIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 2.79 indicates that ALIM has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.79, ALIM perfoms like the industry average, outperforming 45.13% of the companies in the same industry.
  • A Quick Ratio of 2.62 indicates that ALIM has no problem at all paying its short term obligations.
  • The Quick ratio of ALIM (2.62) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.62
ALIM Yearly Current Assets VS Current LiabilitesALIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • ALIM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.66%, which is quite impressive.
  • Looking at the last year, ALIM shows a very strong growth in Revenue. The Revenue has grown by 69.76%.
  • The Revenue has been growing by 11.62% on average over the past years. This is quite good.
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%

3.2 Future

  • Based on estimates for the next years, ALIM will show a very strong growth in Earnings Per Share. The EPS will grow by 22.30% on average per year.
  • Based on estimates for the next years, ALIM will show a very strong growth in Revenue. The Revenue will grow by 23.81% on average per year.
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALIM Yearly Revenue VS EstimatesALIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
ALIM Yearly EPS VS EstimatesALIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • ALIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • ALIM is valuated quite expensively with a Price/Forward Earnings ratio of 28.59.
  • 77.44% of the companies in the same industry are more expensive than ALIM, based on the Price/Forward Earnings ratio.
  • ALIM's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.06.
Industry RankSector Rank
PE N/A
Fwd PE 28.59
ALIM Price Earnings VS Forward Price EarningsALIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALIM is valued a bit cheaper than 77.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28.66
ALIM Per share dataALIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ALIM's earnings are expected to grow with 30.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.56%
EPS Next 3Y30.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ALIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ALIMERA SCIENCES INC

NASDAQ:ALIM (9/13/2024, 8:00:00 PM)

After market: 5.54 0 (0%)

5.54

-0.01 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06
Earnings (Next)10-24
Inst Owners0.2%
Inst Owner Change0%
Ins Owners30.17%
Ins Owner Change0%
Market Cap301.27M
Revenue(TTM)99.68M
Net Income(TTM)-15.27M
Analysts48.89
Price Target5.78 (4.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.01%
Min EPS beat(2)-107.6%
Max EPS beat(2)-60.41%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.13%
Min Revenue beat(2)1.39%
Max Revenue beat(2)2.87%
Revenue beat(4)4
Avg Revenue beat(4)2.76%
Min Revenue beat(4)0.83%
Max Revenue beat(4)5.96%
Revenue beat(8)5
Avg Revenue beat(8)-1.87%
Revenue beat(12)7
Avg Revenue beat(12)-1.43%
Revenue beat(16)10
Avg Revenue beat(16)1.21%
PT rev (1m)0%
PT rev (3m)-29.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 28.59
P/S 3.02
P/FCF N/A
P/OCF N/A
P/B 7.77
P/tB N/A
EV/EBITDA 28.66
EPS(TTM)-0.31
EYN/A
EPS(NY)0.19
Fwd EY3.5%
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS1.83
BVpS0.71
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.16%
ROE -39.38%
ROCE 0.15%
ROIC 0.12%
ROICexc 0.13%
ROICexgc 0.56%
OM 0.2%
PM (TTM) N/A
GM 86.39%
FCFM N/A
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
F-Score4
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Debt/EBITDA 5.55
Cap/Depr 1.81%
Cap/Sales 0.22%
Interest Coverage 0.03
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.62
Altman-Z -1.37
F-Score4
WACC9.95%
ROIC/WACC0.01
Cap/Depr(3y)299.05%
Cap/Depr(5y)185.34%
Cap/Sales(3y)31.69%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%
EBIT growth 1Y101.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3584.36%
EBIT Next 3Y329.62%
EBIT Next 5Y187.7%
FCF growth 1Y62.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3YN/A
OCF growth 5YN/A

ALIMERA SCIENCES INC / ALIM FAQ

What is the fundamental rating for ALIM stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALIM.


Can you provide the valuation status for ALIMERA SCIENCES INC?

ChartMill assigns a valuation rating of 3 / 10 to ALIMERA SCIENCES INC (ALIM). This can be considered as Overvalued.


Can you provide the profitability details for ALIMERA SCIENCES INC?

ALIMERA SCIENCES INC (ALIM) has a profitability rating of 3 / 10.


Can you provide the financial health for ALIM stock?

The financial health rating of ALIMERA SCIENCES INC (ALIM) is 3 / 10.


What is the expected EPS growth for ALIMERA SCIENCES INC (ALIM) stock?

The Earnings per Share (EPS) of ALIMERA SCIENCES INC (ALIM) is expected to grow by 94.02% in the next year.